(NASDAQ: INCY) Incyte's forecast annual revenue growth rate of 8.42% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 78.34%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.8%.
Incyte's revenue in 2025 is $4,584,996,000.On average, 10 Wall Street analysts forecast INCY's revenue for 2025 to be $941,108,580,757, with the lowest INCY revenue forecast at $909,951,685,994, and the highest INCY revenue forecast at $957,261,237,643. On average, 10 Wall Street analysts forecast INCY's revenue for 2026 to be $1,045,561,009,613, with the lowest INCY revenue forecast at $1,000,312,792,950, and the highest INCY revenue forecast at $1,103,607,038,990.
In 2027, INCY is forecast to generate $1,139,153,546,217 in revenue, with the lowest revenue forecast at $1,039,993,881,995 and the highest revenue forecast at $1,275,864,032,018.